Chloroquine-Resistant Plasmodium Falciparum Among Children in Calabar, South Eastern Nigeria

1997 ◽  
Vol 27 (3) ◽  
pp. 146-149 ◽  
Author(s):  
O E Antia-Obong ◽  
A A A Alaribe ◽  
M U Young ◽  
A Bassy ◽  
B V Etim
Keyword(s):  
Plasmodium Falciparum ◽  
Plasmodium Falciparum Malaria ◽  
Chloroquine Resistance ◽  
World Health ◽  
Response To Treatment ◽  
Treatment Groups ◽  
The World ◽  
Health Organization ◽  
The University

Sixty-nine children aged between 6 and 60 months with parasitologically proven Plasmodium falciparum malaria were treated with chloroquine (2.5 mg/kg) in the Children's Emergency Room of the University of Calabar Teaching Hospital (UCTH) in 1993. Thirty subjects (mean age 27.8 months) and 39 (mean age 29.5 months) received chloroquine phosphate suppository (Pharma Deko) and chloroquine sulphate syrup (May & Baker), respectively. The World Health Organization (WHO) 14-day in vivo field test was used in evaluating the response to treatment. In both treatment groups the responses were similar. Overall, parasitological cure occurred in 24 subjects (34.8%) and in the remaining 45 subjects (65.2%) treatment failed (chloroquine resistance). This level of chloroquine resistant Plasmodium falciparum (CRPF) is higher than 53.6% reported in this centre in 1989. Furthermore, in the present study the proportion of RII (46.4%) is significantly higher than 21.4% ( P < 0.02) obtained in 1989. Our findings show a worsening of CRPF in Calabar with RII being the main contributor. This observation indicates the need for continued surveillance of the response of P. falciparum to chloroquine and alternative antimalarials as a means of evolving an effective treatment policy for malaria.

scholarly journals Efficacy of Artesunate-Amodiaquine and Artemether-Lumefantrine for Uncomplicated Plasmodium Falciparum Malaria in Madagascar, 2018

2021 ◽  
Author(s):  
Catherine M. Dentinger ◽  
Tovonahary Angelo Rakotomanga ◽  
Antsa Rakotondrandriana ◽  
Arinomenjanahary Rakotoarisoa ◽  
Marie Ange Rason ◽  
...  
Keyword(s):  
Plasmodium Falciparum ◽  
Molecular Markers ◽  
Artemisinin Resistance ◽  
Plasmodium Falciparum Malaria ◽  
Outcome Data ◽  
World Health ◽  
Antimalarial Resistance ◽  
Health Organization ◽  
Uncomplicated Plasmodium Falciparum Malaria

Abstract Background: Since 2005, artemisinin-based combination therapy (ACT) has been recommended to treat uncomplicated Plasmodium falciparum malaria in Madagascar. Artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) are the first- and second-line treatments, respectively. A therapeutic efficacy study was conducted to assess ACT efficacy and molecular markers of antimalarial resistance.Methods: Children aged six months through 14 years with uncomplicated P. falciparum malaria and a parasitemia of 1,000—100,000 parasites/µl determined by microscopy were enrolled from May—September 2018 in a 28-day in vivo trial using the 2009 World Health Organization protocol for monitoring antimalarial efficacy. Participants from two communes, Ankazomborona (tropical, northwest) and Matanga (equatorial, southeast), were randomly assigned to ASAQ or AL arms. PCR correction was achieved by genotyping seven neutral microsatellites in paired pre- and post-treatment samples. Genotyping assays for molecular markers of resistance in the pfk13, pfcrt, and pfmdr1 genes were conducted.Results: Of 344 patients enrolled, 164/170 (96%) receiving ASAQ and 170/174 (98%) receiving AL completed the study. For ASAQ, the day-28 cumulative PCR-uncorrected efficacy was 100% (95% CI 100–100) and 95% (95% CI 91–100) for Ankazomborona and Matanga, respectively; for AL, it was 99% (95% CI 97–100) in Ankazomborona and 84% (95% CI 76–92) in Matanga. The day-28 cumulative PCR-corrected efficacy for ASAQ was 100% (95% CI 100–100) and 97% (95% CI 94–100%) for Ankazomborona and Matanga, respectively; for AL, it was 100% (95% CI 99–100) in Ankazomborona and 96% (95% CI 91–100) in Matanga. Of 83 successfully sequenced samples for pfk13, no mutations associated with artemisinin resistance were observed. A majority of successfully sequenced samples for pfmdr1 carried either the NFD or NYD haplotypes corresponding to codons 86, 184, and 1246. Of 82 successfully sequenced samples for pfcrt, all were wild type at codons 72–76. Conclusion: PCR-corrected analysis indicated that ASAQ and AL have therapeutic efficacies above the 90% WHO acceptable cut-off. We did not observe any genetic evidence of resistance to artemisinin, consistent with the clinical outcome data. However, the most common pfmdr1 haplotypes were NYD and NFD, previously associated with tolerance to lumefantrine.

scholarly journals Optimizing COVID-19 testing capabilities and clinical management using pathology informatics

JAMIA Open ◽  
2020 ◽  
Author(s):  
Srikar Chamala ◽  
Sherri Flax ◽  
Petr Starostik ◽  
Kartikeya Cherabuddi ◽  
Nicole M Iovine ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Clinical Management ◽  
World Health ◽  
University Of Florida ◽  
Pathology Informatics ◽  
Large Numbers ◽  
The World ◽  
Health Organization ◽  
The University ◽  
Reporting Data

Abstract Coronavirus disease 2019, first reported in China in late 2019, has quickly spread across the world. The outbreak was declared a pandemic by the World Health Organization on March 11, 2020. Here, we describe our initial efforts at the University of Florida Health for processing of large numbers of tests, streamlining data collection, and reporting data for optimizing testing capabilities and superior clinical management. Specifically, we discuss clinical and pathology informatics workflows and informatics instruments which we designed to meet the unique challenges of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing. We hope these results benefit institutions preparing to implement SARS-CoV-2 testing.

scholarly journals Survey of Radon Concentrations in the University of Granada in Southern Spain

2021 ◽  
Vol 18 (6) ◽  
pp. 2885
Author(s):  
Irene Calvente ◽  
María Isabel Núñez ◽  
Rachid Chahboun Karimi ◽  
Juan Villalba-Moreno
Keyword(s):  
Southern Spain ◽  
World Health ◽  
Maximal Level ◽  
15Th Century ◽  
The World ◽  
Time Periods ◽  
Health Organization ◽  
The University ◽  
Analyze Data ◽  
Radon Concentrations

The objective of this pilot study was to gather and analyze data on radon concentrations in workplaces in three buildings of Granada University (Southern Spain) constructed in different centuries. All measurements were made at basement or ground floor level under normal use conditions except for one space (mineral store), in which measurements were compared between the door closed and open. Measurements were conducted during different time periods between October 2013 and March 2019 with a Radon-Scout PLUS portable Radonmonitor. The duration of continuous recordings at different sites ranged between 42 and 1104 h. Mean accumulated radon concentrations ranged between 12 and 95 Bq/m3, below the maximal level of 300 Bq/m3 set by the World Health Organization (WHO). Relatively high values were recorded in the oldest building (15th century), which was also poorly ventilated. Ventilation appeared to be an important factor in reducing radon levels, especially in areas less exposed to radon, such as Southern Spain.

COVID-19: implications for NHS Staff

2020 ◽  
Vol 14 (4) ◽  
pp. 193-197
Author(s):  
Alan Glasper
Keyword(s):  
World Health ◽  
The Novel ◽  
Emeritus Professor ◽  
The World ◽  
Clinical Environments ◽  
Public Health Institutions ◽  
Health Institutions ◽  
Health Organization ◽  
The University

In light of the emergence in China of COVID-19, the novel corona virus, emeritus professor Alan Glasper, from the University of Southampton discusses the role of the World Health Organization and other public health institutions in responding to potential new global pandemics and deliberates on the role of NHS staff in coping with infectious disease in clinical environments.

scholarly journals Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine

2019 ◽  
Author(s):  
Petter I. Andersen ◽  
Klara Krpina ◽  
Aleksandr Ianevski ◽  
Nastassia Shtaida ◽  
Eunji Jo ◽  
...  
Keyword(s):  
Influenza A ◽  
Rift Valley Fever Virus ◽  
Antiviral Agents ◽  
Viral Disease ◽  
World Health ◽  
Valley Fever ◽  
The World ◽  
Health Organization ◽  
Hiv 1

Viruses are the major causes of acute and chronic infectious diseases in the world. According to the World Health Organization, there is an urgent need for better control of viral diseases. Re-purposing existing antiviral agents from one viral disease to another could play a pivotal role in this process. Here we identified novel activities of obatoclax and emetine against herpes simplex virus type 2 (HSV-2), human immunodeficiency virus 1 (HIV-1), echovirus 1 (EV1), human metapneumovirus (HMPV) and Rift Valley fever virus (RVFV) in cell cultures. Moreover, we demonstrated novel activities of emetine against influenza A virus (FluAV), niclosamide against HSV-2, brequinar against HIV-1, and homoharringtonine against EV1. Our findings may expand the spectrum of indications of these safe-in-man agents and reinforce the arsenal of available antiviral therapeutics pending the results of further in vivo tests.

A comparison of malarial antigens from human and Aotus monkey blood infected with Plasmodium falciparum

Parasitology ◽  
1972 ◽  
Vol 64 (2) ◽  
pp. 191-195 ◽  
Author(s):  
R. J. M. Wilson ◽  
A. Voller
Keyword(s):  
Plasmodium Falciparum ◽  
Great Britain ◽  
Human Blood ◽  
Research Council ◽  
Medical Research Council ◽  
Financial Assistance ◽  
World Health ◽  
The World ◽  
Health Organization ◽  
Overseas Development

An extract of blood from Aotus monkeys infected with Plasmodium falciparum contained all the clones of malaria precipitins so far identified in human blood.We are grateful to the Medical Research Council and Overseas Development Administration of Great Britain and to the World Health Organization for their financial assistance.

Influence of the Estrous Cycle on the Action of Oxytocin on Rat Ovarian Contractility in Vivo**Supported in part by the World Health Organization.

1977 ◽  
Vol 28 (2) ◽  
pp. 205-208 ◽  
Author(s):  
Ricardo A. Roca ◽  
Elsa G. Garófalo ◽  
Héctor Píriz ◽  
Idivia Martino ◽  
Gloria Rieppi
Keyword(s):  
World Health Organization ◽  
Estrous Cycle ◽  
World Health ◽  
The World ◽  
Health Organization

scholarly journals Efficacy of Artemether-Lumefantrine for the Treatment of Plasmodium falciparum Malaria in Bohicon and Kandi, Republic of Benin, 2018–2019

2021 ◽  
Author(s):  
Augustin Kpemasse ◽  
Fortune Dagnon ◽  
Ramani Saliou ◽  
Alexis Sacca Yarou Maye ◽  
Cyriaque Dossou Affoukou ◽  
...  
Keyword(s):  
Plasmodium Falciparum ◽  
Plasmodium Falciparum Malaria ◽  
World Health ◽  
Antimalarial Resistance ◽  
Resistance Markers ◽  
Republic Of Benin ◽  
Health Organization ◽  
Treatment Policies ◽  
Parasitological Response ◽  
C580y Mutation

In 2005, artemether-lumefantrine (AL), an artemisinin-based combination therapy, was introduced as the first-line treatment of uncomplicated Plasmodium falciparum malaria in Benin. Per World Health Organization recommendations to monitor the efficacy of antimalarial treatment, we conducted a therapeutic efficacy study with AL for uncomplicated P. falciparum malaria in Bohicon and Kandi, Benin, from 2018 to 2019. Febrile patients aged 6 to 59 months with confirmed P. falciparum monoinfection received supervised doses of AL for 3 days. We monitored patients clinically and parasitologically on days 1, 2, 3, 7, 14, 21, and 28. A molecular analysis to detect mutations in the P. falciparum Kelch propeller gene (Pfk13) gene was carried out on day 0 samples. A total of 205 patients were included in the study. In Bohicon, the uncorrected adequate clinical and parasitological response (ACPR) proportion was 91.3% (95% confidence interval [CI]: 84.6–95.8%), whereas in Kandi this proportion was 96.7% (95% CI: 90.6–99.3%). Genotype-corrected ACPR proportions were 96.3% (95% CI: 90.9–99.0%) and 96.7% (95% CI: 90.6–99.3%) in Bohicon and Kandi, respectively. On day 3, 100% of patients in Bohicon and 98.9% of patients in Kandi had undetectable parasitemia. The C580Y mutation in the Pfk13 gene was not observed. AL remains effective for P. falciparum malaria in these two sites in Benin. Monitoring antimalarial efficacy and prevalence of molecular-resistance markers in Benin should be continued to allow for early detection of antimalarial resistance and to guide treatment policies.

Converting to a Synchronous Virtual Nursing Research Conference Amidst a Pandemic: A Case Study

2021 ◽  
Vol 27 (2) ◽  
pp. 118-124
Author(s):  
Lilian J. Canamo ◽  
Jessica P. Bejar ◽  
Judy E. Davidson
Keyword(s):  
World Health Organization ◽  
Large Scale ◽  
University Of California ◽  
World Health ◽  
User Engagement ◽  
Research Conference ◽  
The World ◽  
Health Organization ◽  
The University

University of California San Diego Health was set to launch its 13th annual Nursing and Inquiry Innovation Conference event in June 2020. However, the Coronavirus Disease 2019 (COVID-19) pandemic placed a barrier to large gatherings throughout the world. Because the World Health Organization designated 2020 as the Year of the Nurse and Midwife, the University committed to continuing the large-scale conference, converting to a virtual event. This article reviews the methodologies behind the delivery of the virtual event and implications for user engagement and learning on the blended electronic platform.

Artemether and imatinib combination therapy against malaria infection

2021 ◽  
Vol 19 (1) ◽  
pp. 139-143
Author(s):  
A.V. Kondrashin ◽  
◽  
E.V. Stepanova ◽  
L.F. Morozova ◽  
V.P. Sergiev ◽  
...  
Keyword(s):  
Combination Therapy ◽  
World Health ◽  
In Vivo Studies ◽  
Telomerase Inhibitors ◽  
Combined Use ◽  
The World ◽  
Oncological Diseases ◽  
Health Organization ◽  
Key Words Malaria

Artemisinin-based combination therapy (ACT) is recommended by the World Health Organization (WHO) as the first and second line of treatment for uncomplicated malaria caused by P. falciparum, as well as for chloroquine-resistant P. vivax malaria. Despite the large number of antimalarial drugs, there is no any ideal drug, since each individual combination of drugs or monotherapy have their own limitations, ranging from their triple (activity) in relation to certain forms of the development of Plasmodium in the human body, side effects, toxicity and resistance. During the course of the study carried out, the most promising compound-candidate was selected – imatinib, which is currently used as targeted therapy for a number of oncological diseases. The objective of this work is to evaluate the efficacy of the combined use of imatinib and artemether in vivo studies on the human malarial model – the rodent malaria parasites Plasmodium berghei. Dut to the optimally selected treatment scheme, it was possible to reduce the dosage of imatinib twice – to 0,25 mg/kg, and that of artemether three times – to 33 mg/kg. The use of this scheme made it possible to considerably reduce the toxic effect of these drugs due to the potentiation of antimalarial effect. Key words: malaria, drug resistance, telomerase inhibitors, imatinib, chemotherapy of malaria

Sign in / Sign up

Export Citation Format

Share Document